Organization
Nnanning
1 abstract
Abstract
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.Org: Guangxi Medical University Cancer Hospital, Nanning, China, China National Biotec Group, Nnanning,